<DOC>
	<DOCNO>NCT02363075</DOCNO>
	<brief_summary>The main purpose study estimate efficiency 3 month dexamfetamine sulphate MFI 20 scale severe fatigue patient stabilize glioma .</brief_summary>
	<brief_title>Dexamfetamine Sulphate Patients With Glioma Suffering From Severe Asthenia</brief_title>
	<detailed_description>Quality life patient stabilize gliomas often impact severe physical psychological fatigue result tumor side effect treatment . It randomize double blind Placebo-Controlled Trial evaluate effect dexamfetamine sulphate severe fatigue glioma patient . Half participant receive dexamfetamine sulphate half receive placebo . Neither participant study doctor know group . The main objective ass impact 3 month dexamfetamine sulphate patient suffer RANO stable responsive glioma complain severe fatigue ( quantified Multidimensional Fatigue inventory - MFI 20 scale ) . The secondary objective include : evaluation side effect , quality life , cognitive function , depression , variation time fatigue scale MFI 20 VAS . 58 patient include . In patient complain severe asthenia , non progressive neuro-oncological disease , without criterion depression reveal HAD ( Hospital Anxiety Depression ) scale , evaluation fatigue do MFI 20 scale . Patients MFI 20 score ≥60/100 correspond inclusion criterion invite participate . After randomisation , baseline evaluation do , include MFI20 , Norris VAS , EORTC QLQ-C30 , Mattis scale , Trail Making Test , Grober Buschke , Wisconsin Card Sorting Test , HAD scale Marin scale . Patients receive , double blinded way , six pill day either dexamphetamine sulfate ( 15 mg*2 ) placebo , 3 month , initial phase progressive increasing level dose every 10 day , depend tolerance . The evaluation fatigue , quality life do every month 3 month treatment . The cognitive evaluation do 3 month . The main criterion evaluation variation 3 month MFI 20 score non progressive patient .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Asthenia</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>Inclusion criterion : Patients complain severe asthenia define MFI 20 score ≥ 60/100 Patients suffer histologically proven glioma Patients responsive stable disease ( accord RANO criterion ) least 3 month , either still chemotherapy simple surveillance stable dosage steroid least 1 week Time elapse postradiotherapy 3 month HAD score depression ≤8 Karnofsky performance index ≥ 60 ≥ 18 year age contraceptive measure write informed consent Depending french system health assurance Exclusion criterion : Severe aphasia symptom compromise test execution concomitant uncontrolled pathology Known symptomatic constitutional cardiovascular disease , ( cardiac arrhythmia , recent myocardial infarction , chest pain , history unstable angina ) and/or uncontrolled hypertension , ( ≥ 16/10 ) , arteriosclerosis , cardiac abnormality detect initial cardiac echography . Hyperthyroidism Known hypersensitivity dexamphetamine relate compound Glaucoma Porphyria Hemoglobin level le 10,0 g/dL Alcohol drug abuse , Agitation Tourette 's syndrome Patients receive MAO inhibitor past 14 day Hereditary hypersensitivity galactose , Lapp lactase deficiency glucosegalactose malabsorption syndrome Hereditary hypersensitivity saccharose , glucosegalactose malabsorption syndrome saccharaseisomaltase deficiency Pregnant lactate woman Non french speaker History psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>dexamfetamine sulphate</keyword>
	<keyword>severe asthenia</keyword>
	<keyword>glioma</keyword>
	<keyword>MFI-20</keyword>
	<keyword>double-blind</keyword>
	<keyword>stabilisation phase</keyword>
</DOC>